Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) EBT Margin (2022 - 2025)

Historic EBT Margin for Taysha Gene Therapies (TSHA) over the last 4 years, with Q2 2025 value amounting to 1254.33%.

  • Taysha Gene Therapies' EBT Margin rose 5339800.0% to 1254.33% in Q2 2025 from the same period last year, while for Sep 2025 it was 1492.06%, marking a year-over-year decrease of 6710300.0%. This contributed to the annual value of 1015.49% for FY2024, which is 5374300.0% down from last year.
  • Taysha Gene Therapies' EBT Margin amounted to 1254.33% in Q2 2025, which was up 5339800.0% from 873.76% recorded in Q1 2025.
  • Over the past 5 years, Taysha Gene Therapies' EBT Margin peaked at 7486.46% during Q1 2022, and registered a low of 1788.31% during Q2 2024.
  • Moreover, its 4-year median value for EBT Margin was 540.88% (2023), whereas its average is 697.92%.
  • Per our database at Business Quant, Taysha Gene Therapies' EBT Margin crashed by -78607500bps in 2023 and then soared by 5339800bps in 2025.
  • Over the past 4 years, Taysha Gene Therapies' EBT Margin (Quarter) stood at 4220.08% in 2022, then plummeted by -110bps to 417.26% in 2023, then crashed by -116bps to 902.77% in 2024, then plummeted by -39bps to 1254.33% in 2025.
  • Its EBT Margin was 1254.33% in Q2 2025, compared to 873.76% in Q1 2025 and 902.77% in Q4 2024.